EA201992116A1 - Фармацевтические составы флороглюцинола и триметилфлороглюцинола - Google Patents

Фармацевтические составы флороглюцинола и триметилфлороглюцинола

Info

Publication number
EA201992116A1
EA201992116A1 EA201992116A EA201992116A EA201992116A1 EA 201992116 A1 EA201992116 A1 EA 201992116A1 EA 201992116 A EA201992116 A EA 201992116A EA 201992116 A EA201992116 A EA 201992116A EA 201992116 A1 EA201992116 A1 EA 201992116A1
Authority
EA
Eurasian Patent Office
Prior art keywords
trimethylfloroglucinol
floroglucinol
pharmaceutical compositions
phloroglucinol
patient
Prior art date
Application number
EA201992116A
Other languages
English (en)
Inventor
Пиюш Патель
Кэтрин Пирс
Джонатан Исейексон
Original Assignee
СИНРКС ФАРМА, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by СИНРКС ФАРМА, ЭлЭлСи filed Critical СИНРКС ФАРМА, ЭлЭлСи
Publication of EA201992116A1 publication Critical patent/EA201992116A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Abstract

Изобретение относится к фармацевтической композиции флороглюцинола и/или триметилфлороглюцинола и/или их фармацевтически приемлемой соли для перорального введения пациенту.
EA201992116A 2017-03-08 2018-03-08 Фармацевтические составы флороглюцинола и триметилфлороглюцинола EA201992116A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762468501P 2017-03-08 2017-03-08
PCT/US2018/021505 WO2018165404A1 (en) 2017-03-08 2018-03-08 Pharmaceutical formualtions of phloroglucinol and trimethylphloroglucinol

Publications (1)

Publication Number Publication Date
EA201992116A1 true EA201992116A1 (ru) 2020-01-29

Family

ID=61768496

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992116A EA201992116A1 (ru) 2017-03-08 2018-03-08 Фармацевтические составы флороглюцинола и триметилфлороглюцинола

Country Status (12)

Country Link
US (1) US20200009076A1 (ru)
EP (1) EP3592337B1 (ru)
JP (2) JP7323451B2 (ru)
KR (1) KR102636273B1 (ru)
CN (1) CN110381925A (ru)
AU (1) AU2018231044B2 (ru)
BR (1) BR112019016091A2 (ru)
CA (1) CA3053254C (ru)
DK (1) DK3592337T3 (ru)
EA (1) EA201992116A1 (ru)
ES (1) ES2958616T3 (ru)
WO (1) WO2018165404A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112535659B (zh) * 2019-09-20 2022-03-22 南京艾德凯腾生物医药有限责任公司 一种间苯三酚注射液的配制方法
TW202136194A (zh) 2019-12-20 2021-10-01 香港商凱瑞康寧有限公司 ４－纈胺醯氧基丁酸的合成方法
CN113750058B (zh) * 2020-06-01 2023-07-04 北京九能天远科技有限公司 一种间苯三酚冻干口崩片及其制备方法
CN115803017A (zh) 2020-06-18 2023-03-14 凯瑞康宁生物工程有限公司 水溶性活性药物成分的药物造粒物
JP2023537195A (ja) * 2020-06-18 2023-08-31 エックスダブリューファーマ リミテッド 水溶性医薬品有効成分の制御放出造粒物
CN116261451A (zh) 2020-07-24 2023-06-13 凯瑞康宁生物工程有限公司 γ-羟基丁酸衍生物的药物组合物和药物动力学
AU2021357705A1 (en) 2020-10-05 2023-05-18 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
JP2024511991A (ja) 2021-03-19 2024-03-18 エックスダブリューファーマ リミテッド ガンマ－ヒドロキシ酪酸誘導体の組み合わされた放出製剤の薬物動態
CN113304109A (zh) * 2021-06-08 2021-08-27 内蒙古大唐药业股份有限公司 一种醋柳黄酮固体脂质纳米粒分散液及其制备方法
CN115282132B (zh) * 2022-02-10 2024-01-30 郑州大学第一附属医院 用于缓解ercp胆道痉挛的复合物及其制备方法
WO2023244591A1 (en) * 2022-06-13 2023-12-21 Cinphloro Pharma Llc Phloroglucinol formulations and methods of use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773031A (en) 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
AU736912B2 (en) 1997-02-20 2001-08-02 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
JP4974419B2 (ja) 2001-06-12 2012-07-11 東和薬品株式会社 薬物含有徐放性顆粒およびそれを含む錠剤
ITMI20020514A1 (it) 2002-03-12 2003-09-12 Jagotec Ag Sistema terapeutico per il rilascio controllato di uno o piu' principi attivi
HUE031650T2 (en) 2002-10-01 2017-07-28 Banner Life Sciences Llc Enterosolvent preparation for soft capsule wall production
US7825106B2 (en) 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US8846100B2 (en) 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
AU2007357647A1 (en) 2007-08-15 2009-02-19 Mcneil-Ppc, Inc. Immediate release and sustained release ibuprofen dosing regimen
US20090148532A1 (en) 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms
MX348282B (es) 2009-02-13 2017-06-05 Romark Laboratories L C * Formulaciones farmaceuticas de liberacion controlada de nitazoxanida.
JP5827952B2 (ja) * 2009-10-09 2015-12-02 ユンジン・ファーム・カンパニー・リミテッドＹｕｎｇｊｉｎ Ｐｈａｒｍ． Ｃｏ． Ｌｔｄ． 速効性と持続性を同時に有する薬剤学的組成物
KR101320802B1 (ko) * 2010-02-16 2013-10-23 주식회사 드림파마 방출 제어형 사포그릴레이트 염산염 함유 다층 정제
FR2984165B1 (fr) * 2011-12-16 2014-06-27 Pharmeuro Traitement des crises de migraines, notamment d'algies vasculaires de la face
EP2968994B1 (en) 2013-03-15 2018-08-15 Aprecia Pharmaceuticals LLC Rapid disperse dosage form containing levetiracetam
US20160113913A1 (en) 2013-04-19 2016-04-28 Takeda Pharmaceutical Company Limited Controlled-release drug formulation
CN103494792B (zh) 2013-08-27 2015-03-04 寿光富康制药有限公司 一种复方间苯三酚冻干口腔崩解片及制备方法
KR101587142B1 (ko) * 2013-12-26 2016-01-21 한국유나이티드제약 주식회사 속방층과 2개의 서방층으로 이루어진 위장관 질환 치료용 모사프리드 구연산염 삼층정 서방제제
MX2017015579A (es) * 2015-06-04 2018-03-27 Pfizer Formas de dosificacion solidas de palbociclib.
KR101758451B1 (ko) * 2015-06-10 2017-07-27 대화제약 주식회사 안정성이 개선된 플로로글루시놀 무수물 함유 속용성 정제의 제조방법

Also Published As

Publication number Publication date
DK3592337T3 (da) 2023-09-18
CA3053254C (en) 2024-02-20
ES2958616T3 (es) 2024-02-12
KR20190122218A (ko) 2019-10-29
BR112019016091A2 (pt) 2020-04-14
WO2018165404A8 (en) 2019-09-12
CA3053254A1 (en) 2018-09-13
AU2018231044A1 (en) 2019-08-08
AU2018231044B2 (en) 2023-04-06
WO2018165404A1 (en) 2018-09-13
AU2018231044A8 (en) 2019-10-03
JP2020510000A (ja) 2020-04-02
US20200009076A1 (en) 2020-01-09
KR102636273B1 (ko) 2024-02-16
JP2023116518A (ja) 2023-08-22
JP7323451B2 (ja) 2023-08-08
EP3592337B1 (en) 2023-07-05
CN110381925A (zh) 2019-10-25
EP3592337A1 (en) 2020-01-15

Similar Documents

Publication Publication Date Title
EA201992116A1 (ru) Фармацевтические составы флороглюцинола и триметилфлороглюцинола
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
EA201890654A1 (ru) Терапевтические композиции для лечения вируса иммунодефицита человека
PH12018501956A1 (en) 3-desoxy derivative and pharmaceutical compositions thereof
EA202090486A3 (ru) Соединения для лечения спинальной мышечной атрофии
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
EA202090573A1 (ru) Составы нирапариба
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
EA201792591A1 (ru) Фармацевтические препараты
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
MD3359146T2 (ro) Compoziții farmaceutice și utilizări direcționate spre bolile de depozitare lizozomală
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
EA202191114A1 (ru) Производные пиридинилсульфонамида, фармацевтические композиции и их применение
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
EA201692298A1 (ru) Производные карбоксамидов
ZA202103090B (en) Pharmaceutical formulations of cyclosporine analogs
MX2019012522A (es) Compuestos y metodos terapeuticos.
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
EA202091561A1 (ru) Фармацевтическая композиция, содержащая фармацевтически приемлемую кислотно-аддитивную соль леналидомида
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
EA201890929A1 (ru) Низкие дозировки композиций дипиридамола для перорального приема и их использование
PH12020500120A1 (en) Pharmaceutical compositions
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний
EA201992754A1 (ru) Фармацевтические композиции
TR201722852A2 (tr) Mesalazi̇ni̇n oral farmasöti̇k kompozi̇syonlari